Business Context and Reporting Period
This Form 8-K is filed by Black Hawk Acquisition Corporation (BKHA), a Cayman Islands-based special purpose acquisition company (SPAC), on February 3, 2026. The report discloses material events concerning Vesicor Therapeutics, Inc., the Company's proposed business combination target.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either Black Hawk Acquisition Corporation or Vesicor Therapeutics, Inc. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure of CFO: Michael Bowen, the Chief Financial Officer of Vesicor Therapeutics, Inc., passed away on January 27, 2026.
- Appointment of New CFO: Mitchell Creem was appointed as the new Chief Financial Officer of Vesicor, effective immediately on January 27, 2026. No employment agreement exists between Vesicor and Mr. Creem at this time.
- Board Expansion: Frederick Woodruff Field was appointed as a member of the Vesicor Board of Directors on January 26, 2026. The Board determined he satisfies Nasdaq independence requirements.
Management Commentary and Background
Mitchell Creem: Mr. Creem brings over 35 years of senior executive experience in healthcare. He currently serves as CEO and director of Pioneer Acquisition Corporation (PACH). His background includes roles as CFO at ApolloMed (now Astrana Health), Keck Hospital of USC, UCLA Health Sciences, and Beth Israel Deaconess Medical Center. He holds a BS in Accounting from Boston University and an MHA from Duke University.
Frederick Woodruff Field: Mr. Field is an executive and entrepreneur with over 30 years of experience in film, music, and television. He is the founder and CEO of Radar Pictures and co-founded Interscope Records. Vesicor believes his experience as an investor and executive qualifies him for the board.
The filing states there are no family relationships between the new appointees and existing directors or officers, and no undisclosed arrangements influenced their selection.
Investor Verification Checklist
- Verify the status of the proposed business combination between Black Hawk Acquisition Corporation and Vesicor Therapeutics following the sudden departure of Vesicor's CFO.
- Confirm whether an employment agreement will be executed with Mitchell Creem and review the terms if disclosed in future filings.
- Assess the impact of the leadership transition on Vesicor's operational stability and the timeline for the merger.
- Review the independence certification of Frederick Woodruff Field in the context of Nasdaq listing rules.